Genzyme Takes Shot At Watson Over Renvela ANDA

Law360, New York (May 25, 2010, 4:21 PM EDT) -- Genzyme Corp. has launched the latest in a string of suits over its kidney disease treatments, accusing Watson Laboratories Inc. of infringing a patent for Renvela through an abbreviated new drug application.

Morristown, N.J.-based Watson in April submitted an ANDA seeking approval of a generic version of an 800 mg dosage of a drug containing the same active ingredient as Renvela, according to a complaint filed Monday in the U.S. District Court for the District of Maryland.

Watson, a manufacturer and distributor of generic pharmaceuticals, said...
To view the full article, register now.